focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,166.00
Bid: 12,132.00
Ask: 12,136.00
Change: -6.00 (-0.05%)
Spread: 4.00 (0.033%)
Open: 12,180.00
High: 12,198.00
Low: 12,076.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FOREX-Dollar firms as U.S. yields tick up ahead of Fed guidance

Wed, 17th Mar 2021 08:50

* Dollar firm after three days of gains ahead of Fed
* Fed 2023 rates projections under scrutiny
* Euro may be hampered by delay in vaccine rollouts
* Graphic: World FX rates https://tmsnrt.rs/2RBWI5E

(Adds comment; updates prices)
By Julien Ponthus
LONDON, March 17 (Reuters) - The U.S. dollar firmed on
Wednesday with 10-year Treasury yields close to 13-month highs
ahead of a Federal Reserve policy meeting which could shed some
light on the timing of future rate hikes and the central bank’s
tolerance for rising yields.
With Fed policymakers expected to forecast the fastest U.S.
economic growth in decades in the wake of COVID-19 vaccinations
and $1.9 trillion in new stimulus, market participants will be
focused on clues that the central bank could start raising rates
in 2023, earlier than it had said.
In any event, expectations of a faster-than-expected
economic recovery will likely weigh.
"U.S. yields might receive further upwards thrust and pull
the dollar along with them in the absence of a clear commitment
on the part of the Fed that a further rise in yields is
undesirable", Commerzbank Antje Praefcke analyst wrote in a
morning note.
She added that because the European Central Bank had in
contrast committed to increase the pace of bond buying to keep a
lid on rising yields, the euro might suffer against the dollar
in the short term.
The euro was down 0.07% at $1.1893 after declining in
the past three sessions.
Hurt by a possible delay in the European Union's vaccination
effort, the euro seemed set to test last week's 3 1/2-month low
of $1.18355.
Europe's medicines watchdog will release results of its
investigation into incidents of bleeding, blood clots and low
platelet counts in recipients of AstraZeneca's
coronavirus vaccine on Thursday afternoon.
Europe's painful recovery from the pandemic is in sharp
contrast with other economies which seem less dependant on
monetary stimulus to pull though.
The Bank of Canada for instance is likely to reduce its bond
purchases as soon as next month, strategists say.
In morning trades in Europe, the dollar index ticked up
0.09% and stood at 91.953, having already risen for three
straight sessions on support mainly from elevated U.S. bond
yields.
Benchmark 10-year Treasury yields were also
ticking up at 1.6340%. They had reached 1.6420% on Friday for
the first time since February 2020.
Against the yen, the greenback firmed 0.15% to 109.14 yen
, hovering near nine-month highs hit this week.
The British pound was up 0.14% at $1.3914 recovering
from profit-taking after it hit a near three-year high last
month on the back of a fast vaccine rollout.
Commodity-linked currencies including the Australian dollar
, the New Zealand dollar and the Canadian dollar
eased slightly against the U.S. dollar, tracking weakness
in commodity prices.
In the cryptocurrency market, bitcoin fell 2.1%
to $55,708.79, slipping further away from a record high of
$61,781.83 hit on Saturday.

========================================================
Currency bid prices at 843 GMT
Description RIC Last U.S. Close Pct Change YTD Pct High Bid Low Bid
Previous Change
Session
Euro/Dollar $1.1894 $1.1903 -0.08% -2.66% +1.1908 +1.1887
Dollar/Yen 109.1250 109.0200 +0.12% +5.67% +109.2000 +109.0950
Euro/Yen 129.80 129.75 +0.04% +2.25% +129.9300 +129.7200
Dollar/Swiss 0.9279 0.9248 +0.34% +4.89% +0.9280 +0.9248
Sterling/Dollar 1.3914 1.3895 +0.14% +1.85% +1.3929 +1.3880
Dollar/Canadian 1.2461 1.2448 +0.10% -2.14% +1.2462 +1.2434
Aussie/Dollar 0.7729 0.7746 -0.19% +0.49% +0.7747 +0.7724
NZ Dollar/Dollar 0.7182 0.7190 -0.11% +0.01% +0.7194 +0.7174


All spots
Tokyo spots
Europe spots
Volatilities
Tokyo Forex market info from BOJ


(Reporting by Hideyuki Sano in Tokyo and Sagarika Jaisinghani
in Bengaluru; Editing by Sam Holmes, Gerry Doyle and Andrew
Cawthorne)

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.